Screening and the prevention of gynecologic cancer: Endometrial cancer

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 20, Issue 2, 2006, Pages 363-377

  Sonoda, Yukio ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Endometrial cancer; Prevention; Risk factors; Screening

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; MISMATCH REPAIR PROTEIN PMS2; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; TAMOXIFEN;

CALORIC INTAKE; CANCER CLASSIFICATION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; COLOR ULTRASOUND FLOWMETRY; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; FAT INTAKE; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GYNECOLOGIC CANCER; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYSTERECTOMY; HYSTEROSCOPY; MASS SCREENING; MENARCHE; MENOPAUSE; OBESITY; PARITY; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; UNITED STATES; UNNECESSARY PROCEDURE; VAGINA BLEEDING; VAGINA DISCHARGE;

ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LIFE STYLE; MASS SCREENING; NEOPLASTIC SYNDROMES, HEREDITARY; REPRODUCTIVE HISTORY; RISK FACTORS; TAMOXIFEN;

EID: 33644879992     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2005.10.015     Document Type: Review

References (69)

1. A. Jemal T. Murray E. Ward et al. Cancer statistics, 2005 CA: A Cancer Journal for Clinicians 55 1 2005 10-30
2. H.A. Hill J.W. Eley L.C. Harlan et al. Racial differences in endometrial cancer survival: The black/white cancer survival study Obstetrics and Gynecology 88 1996 919-926
3. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, & Edwards BK (eds). (1997). SEER Cancer Statistics Review, 1973-1994. Bethesda MD: National Cancer Institute. NIH Publication No. 97-2789.
4. C. Westhoff D. Heller S. Drosinos L. Tancer Risk factors for hyperplasia-associated versus atrophy-associated endometrial carcinoma American Journal of Obstetrics and Gynecology 182 3 2000 506-508
5. A. Akhmedkhanov A. Zeleniuch-Jacquotte P. Toniolo Role of exogenous and endogenous hormones in endometrial cancer. Review of the evidence and research perspectives Annals of the New York Academy of Sciences 943 2001 296-315
6. R.A. Smith V. Cokkinides H.J. Eyre American cancer society guidelines for the early detection of cancer, 2005 CA: A Cancer Journal for Clinicians 55 1 2005 31-44
7. R.J. Kurman R.J. Zaino H.J. Norris Endometrial carcinoma R.J. Kurman Blaustein's Pathology of the Female Genital Tract 4th edn 1994 Springer New York 439-486
8. D.C. Smith R. Prentice D.J. Thompson W.L. Herrmann Association of exogenous estrogen and endometrial carcinoma The New England Journal of Medicine 293 23 1975 1164-1167
9. L.J. Herrinton N.S. Weiss Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma Annals of Epidemiology 3 1993 308-318
10. D.F. Archer The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women Journal of the North American Menopause Society 8 2001 245-251
11. M.C. Pike R.K. Peters W. Cozen et al. Estrogen-progestin replacement therapy and endometrial cancer Journal of the National Cancer Institute 89 1997 1110
12. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. The writing group for the PEPI trial. The Journal of the American Medical Association; 1996; 275(5):370-5.
13. G.L. Anderson H.L. Judd A.M. Kaunitz et al. Women's health initiative investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The women's health initiative randomized trial The Journal of the American Medical Association 290 13 2003 1739-1748
14. M.A. Killackey T.B. Hakes V.K. Pierce Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens Cancer Treatment Reports 69 2 1987 237-238
15. T. Fornander L.E. Rutqvist B. Cedermark et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers Lancet 1 8630 1989 117-120
16. B. Fisher J.P. Costantino D.L. Wickerham et al. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study Journal of the National Cancer Institute 90 18 1998 1371-1388
17. D.L. Wickerham B. Fisher N. Wolmark et al. Association of tamoxifen and uterine sarcoma Journal of Clinical Oncology 20 11 2002 2758-2760
18. M.T. Goodman J.H. Hankin L.R. Wilkens et al. Diet, body size, physical activity, and the risk of endometrial cancer Cancer Research 57 1997 5077-5085
19. C.A. Swanson N. Potischman G.D. Wilbanks et al. Relation of endometrial cancer risk to past and contemporary body size and body fat distribution Cancer Epidemiology Biomarkers and Prevention 2 1993 321-327
20. P. Terry J.A. Baron E. Weiderpass et al. Lifestyle and endometrial cancer risk: A cohort study from the swedish twin registry International Journal of Cancer 82 1999 38-42
21. E. Weiderpass I. Persson H-O. Adami C. Magnusson Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden) Cancer Causes and Control 11 2000 185-192
22. N. Potischman C.A. Swanson P. Siiteri R.N. Hoover Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status Journal of the National Cancer Institute 88 11 1996 756-758
23. E.E. Calle C. Rodriguez K. Walker-Thurmond M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults The New England Journal of Medicine 348 17 2003 1625-1638
24. L. Poretsky M.F. Kalin The gonadotropic function of insulin Endocrine Reviews 8 2 1987 132-141
25. V.G. Garzo J.H. Dorrington Aromatase activity in human granulosa cells during follicular development and the modulation by follicle-stimulating hormone and insulin American Journal of Obstetrics and Gynecology 148 5 1984 657-662
26. J.E. Nestler L.P. Powers D.W. Matt et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome The Journal of Clinical Endocrinology and Metabolism 72 1 1991 83-89
27. F. Parazzini C. La Vecchia E. Negri et al. Diabetes and endometrial cancer: An Italian case-control study International Journal of Cancer 81 4 1999 539-542
28. S.M. Shoff P.A. Newcomb Diabetes, body size, and risk of endometrial cancer American Journal of Epidemiology 148 3 1998 234-240
29. K.E. Anderson E. Anderson P.J. Mink et al. Diabetes and endometrial cancer in the iowa women's health study Cancer Epidemiology Biomarkers and Prevention 10 6 2001 611-616
30. M. Soler L. Chatenoud E. Negri et al. Hypertension and hormone-related neoplasms in women Hypertension 34 2 1999 320-325
31. C.P. McPherson T.A. Sellers J.D. Potter et al. Reproductive factors and risk of endometrial cancer. The iowa women's health study American Journal of Epidemiology 143 12 1996 1195-1202
32. F. Parazzini E. Negri C. La Vecchia et al. Role of reproductive factors on the risk of endometrial cancer International Journal of Cancer 76 6 1998 784-786
33. W.H. Xu Y.B. Xiang Z.X. Ruan et al. Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai International Journal of Cancer 108 4 2004 613-619
34. C.B. Coulam J.F. Annegers J.S. Kranz Chronic anovulation syndrome and associated neoplasia Obstetrics and Gynecology 61 4 1983 403-407
35. K.M. Schmeler P.T. Soliman C.C. Sun et al. Endometrial cancer in young, normal-weight women Gynecologic Oncology 2005 [Epub ahead of print]
36. A.J. Littman S.A. Beresford E. White The association of dietary fat and plant foods with endometrial cancer (United States) Cancer Causes and Control 12 8 2001 691-702
37. N. Potischman C.A. Swanson L.A. Brinton et al. Dietary associations in a case-control study of endometrial cancer Cancer Causes and Control 4 3 1993 239-250
38. M.T. Goodman L.R. Wilkens J.H. Hankin et al. Association of soy and fiber consumption with the risk of endometrial cancer American Journal of Epidemiology 146 4 1997 294-306
39. M. Aarnio R. Sankila E. Pukkala et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes International Journal of Cancer 81 2 1999 214-218
40. P. Watson H.T. Lynch Cancer risk in mismatch repair gene mutation carriers Familial Cancer 1 1 2001 57-60
41. M.G. Dunlop S.M. Farrington A.D. Carothers et al. Cancer risk associated with germline DNA mismatch repair gene mutations Human Molecular Genetics 6 1 1997 105-110
42. K.H. Lu M. Dinh W. Kohlmann et al. Gynecologic cancer as a 'sentinel cancer' for women with hereditary nonpolyposis colorectal cancer syndrome Obstetrics and Gynecology 105 3 2005 569-574
43. A.L. Herbst OCs and genital tract malignancies Dialogues Contracept 4 3 1994 5-7
44. E. Weiderpass H.O. Adami J.A. Baron et al. Use of oral contraceptives and endometrial cancer risk (Sweden) Cancer Causes and Control 10 4 1999 277-284
45. L.F. Voigt Q. Deng N.S. Weiss Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA) Cancer Causes and Control 5 3 1994 227-233
46. J.A. Baron C. La Vecchia F. Levi The antiestrogenic effect of cigarette smoking in women American Journal of Obstetrics and Gynecology 162 2 1990 502-514
47. J.J. Michnovicz R.J. Hershcopf H. Naganuma et al. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking The New England Journal of Medicine 315 21 1986 1305-1309
48. F. Parazzini C. La Vecchia E. Negri et al. Smoking and risk of endometrial cancer: Results from an Italian case-control study Gynecologic Oncology 56 2 1995 195-199
49. L.M. Newcomer P.A. Newcomb A. Trentham-Dietz B.E. Storer Hormonal risk factors for endometrial cancer: Modification by cigarette smoking (United States) Cancer Causes and Control 12 9 2001 829-835
50. A.N. Viswanathan D. Feskanich I. De Vivo et al. Smoking and the risk of endometrial cancer: Results from the nurses' health study International Journal of Cancer 114 6 2005 996-1001
51. A.S. Furberg I. Thune Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort International Journal of Cancer 104 6 2003 669-676
52. L.J. Schouten R.A. Goldbohm P.A. van den Brandt Anthropometry, physical activity, and endometrial cancer risk: Results from the Netherlands Cohort Study Journal of the National Cancer Institute 96 21 2004 1635-1638
53. T. Moradi E. Weiderpass L.B. Signorello et al. Physical activity and postmenopausal endometrial cancer risk (Sweden) Cancer Causes and Control 11 9 2000 829-837
54. J.A. Cauley J.P. Gutai L.H. Kuller et al. The epidemiology of serum sex hormones in postmenopausal women American Journal of Epidemiology 129 6 1989 1120-1131
55. R.A. Smith V. Cokkinides H.J. Eyre American cancer society guidelines for the early detection of cancer, 2005 CA: A Cancer Journal for Clinicians 55 1 2005 31-44
56. M. Aarnio R. Sankila E. Pukkala et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes International Journal of Cancer 81 2 1999 214-218
57. P. Watson H.T. Lynch Cancer risk in mismatch repair gene mutation carriers Familial Cancer 1 1 2001 57-60
58. M.G. Dunlop S.M. Farrington A.D. Carothers et al. Cancer risk associated with germline DNA mismatch repair gene mutations Human Molecular Genetics 6 1 1997 105-110
59. F.P. Dijkhuizen B.W. Mol H.A. Brolmann A.P. Heintz The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: A meta-analysis Cancer 89 8 2000 1765-1772
60. R.S. Guido A. Kanbour-Shakir M.C. Rulin W.A. Christopherson Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer The Journal of Reproductive Medicine 40 8 1995 553-555
61. D.F. Archer K. McIntyre-Seltman W.W. Wilborn Jr et al. Endometrial morphology in asymptomatic postmenopausal women American Journal of Obstetrics and Gynecology 165 2 1991 317-320
62. S. Duffy T.L. Jackson M. Lansdown et al. The ATAC adjuvant breast cancer trial in postmenopausal women: Baseline endometrial subprotocol data British Journal of Obstetrics and Gynaecology 110 12 2003 1099-1106
63. A.C. Fleischer J.E. Wheeler I. Lindsay et al. An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms American Journal of Obstetrics and Gynecology 184 2 2001 70-75
64. R.D. Langer J.J. Pierce K.A. O'Hanlan et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal estrogen/progestin interventions trial The New England Journal of Medicine 337 25 1997 1792-1798
65. M. Gambacciani P. Monteleone M. Ciaponi et al. Clinical usefulness of endometrial screening by ultrasound in asymptomatic postmenopausal women Maturitas 48 4 2004 421-424
66. B. Gerber A. Krause H. Muller et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound Journal of Clinical Oncology 18 20 2000 3464-3470
67. C.D. Love B.B. Muir J.B. Scrimgeour et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening Journal of Clinical Oncology 17 7 1999 2050-2054
68. M.F. Fung A. Reid W. Faught et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen Gynecologic Oncology 91 1 2003 154-159
69. R.R. Barakat T.A. Gilewski L. Almadrones et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy Journal of Clinical Oncology 18 20 2000 3459-3463